The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing.

Autor: Köstek O; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Demirel A; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Hacıoğlu MB; Department of Medical Oncology, Trakya University, Istanbul, Turkiye., Tastekin D; Department of Medical Oncology, Istanbul University, Istanbul, Turkiye., Karabulut S; Department of Medical Oncology, Istanbul University, Istanbul, Turkiye., Gündogdu A; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Sever N; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Ayhan M; Clinic of Medical Oncology, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkiye., Çelebi A; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Majidova N; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Yaşar A; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Ağyol Y; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Erel P; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Kocaaslan E; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Güren AK; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Arıkan R; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Isık S; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Ercelep O; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Goksu SS; Department of Medical Oncology, Antalya University, Antalya, Turkiye., Alandag C; Department of Medical Oncology, Cumhuriyet University, Sivas, Turkiye., Bilgetekin İ; Dr Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkiye., Caner B; Department of Medical Oncology, Uludag University, Bursa, Turkiye., Sahin AB; Department of Medical Oncology, Uludag University, Bursa, Turkiye., Gulmez A; Faculty of Medicine, Department of Medical Oncology, Inonu University, Malatya, Turkey., Akagunduz B; Clinic of Medical Oncology, Mengucekgazi Training and Research Hospital, Erzincan, Turkiye., Kose F; Department of Medical Oncology, Baskent University, Adana, Turkiye., Kaplan MA; Department of Medical Oncology, Dicle University, Diyarbakir, Turkiye., Dogan E; Department of Medical Oncology, Erciyes University, Kayseri, Turkiye., Sakalar T; Department of Medical Oncology, Erciyes University, Kayseri, Turkiye., Guven DC; Department of Medical Oncology, Hacettepe University, Ankara, Turkiye., Gurbuz M; Department of Medical Oncology, Ankara University, Ankara, Turkiye., Ergun Y; Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkiye., Karaagac M; Department of Medical Oncology, Necmettin Erbakan University, Konya, Turkiye., Turker S; Clinic of Medical Oncology, Ankara Dışkapı Yıldırım Beyazıt Research and Training Hospital, Ankara, Turkiye., Ozkul O; Department of Medical Oncology, Sakarya University, Sakarya, Turkıye., Yıldız B; Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey., Sahin S; Department of Medical Oncology, Van Education and Research Hospital, Van, Turkey., Demiray AG; Department of Medical Oncology, Pamukkale University, Denizli, Turkiye., Sari M; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Erdogan B; Department of Medical Oncology, Trakya University, Istanbul, Turkiye., Hacıbekiroglu İ; Department of Medical Oncology, Sakarya University, Sakarya, Turkıye., Çakmak Öksüzoğlu ÖB; Dr Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkiye., Kilickap S; Department of Medical Oncology, Hacettepe University, Ankara, Turkiye., Bilici A; Department of Medical Oncology, Medipol University, Istanbul, Turkiye., Bayoglu İV; Department of Medical Oncology, Marmara University, Istanbul, Turkiye., Topaloglu S; Department of Medical Oncology, Trakya University, Istanbul, Turkiye., Cicin İ; Department of Medical Oncology, Trakya University, Istanbul, Turkiye.

Publikováno v: Journal of chemotherapy (Florence, Italy) [J Chemother] 2024 Nov; Vol. 36 (7), pp. 613-621. Date of Electronic Publication: 2024 Jan 23.

Age-adjusted Charlson Comorbidity Index is a valuable prognostic tool in operable soft tissue sarcoma of trunk and extremities.

Autor: Telli TA; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey. Electronic address: tugbaakintelli@gmail.com., Alan O; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey; Department of Medical Oncology, Faculty of Medicine, Koç University, Istanbul, Turkey., Demircan NC; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Sariyar N; Department of Internal Medicine, Faculty of Medicine, Marmara University, Istanbul, Turkey., Arikan R; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Basoglu T; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Yasar A; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Celebi A; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Isik S; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Sofulu O; Department of Orthopaedic Surgery and Traumatology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Erol B; Department of Orthopaedic Surgery and Traumatology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Turkoz HK; Department of Pathology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Ozgen Z; Department of Radiation Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Ercelep O; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Dane F; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey., Yumuk PF; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey; Department of Medical Oncology, Faculty of Medicine, Koç University, Istanbul, Turkey.

Publikováno v: Orthopaedics & traumatology, surgery & research : OTSR [Orthop Traumatol Surg Res] 2023 May; Vol. 109 (3), pp. 103491. Date of Electronic Publication: 2022 Nov 28.

Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group.

Autor: Dogan I; Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34093, Turkey., Aksoy S; Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara 06100, Turkey., Cakar B; Department of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, Turkey., Basaran G; Department of Medical Oncology, Acibadem University, Altunizade Acibadem Hospital, Istanbul 34662, Turkey., Ercelep O; Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul 34722, Turkey., Molinas Mandel N; Department of Medical Oncology, Koç University Amerikan Hospital, Istanbul 34010, Turkey., Korkmaz T; Department of Medical Oncology, Acibadem University, Maslak Acibadem Hospital, Istanbul 34457, Turkey., Gokmen E; Department of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, Turkey., Sener C; Incidence Medical Research and Biostatistics Consultancy Services, Istanbul 34440, Turkey., Aydiner A; Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34093, Turkey., Saip P; Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul 34093, Turkey., Eralp Y; Research Institute of Senology, Acıbadem University, Maslak Acıbadem Hospital, Istanbul 34457, Turkey.

Publikováno v: Cancers [Cancers (Basel)] 2023 Mar 08; Vol. 15 (6). Date of Electronic Publication: 2023 Mar 08.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study

Autor: Oruc, Z. and Kaplan, M.A. and Geredeli, C. and Sari, N.Y. and Ozaslan, E. and Aytekin, A. and Elkiran, E.T. and Koca, S. and Dogan, M. and Turan, N. and Yuce, O. and Sevinc, A. and Ercelep, O. and Isikdogan, A.

Purpose: This study aimed to analyze prognostic factors for survival and the reliability and the effectiveness of eribulin therapy in metastatic breast cancer (MBC) patients. Methods: A total of 80 patients treated with eribulin in 12 medical oncolog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::21c8ff54518ae1afa576aa61c13a6efb
http://hdl.handle.net/20.500.12481/11949